Literature DB >> 17981268

Functional expression of B7H1 on retinal pigment epithelial cells.

Yoshihiko Usui1, Yoko Okunuki, Takaaki Hattori, Takeshi Kezuka, Hiroshi Keino, Nobuyuki Ebihara, Sunao Sugita, Masahiko Usui, Hiroshi Goto, Masaru Takeuchi.   

Abstract

The interaction of programmed death-1 (PD-1) expressed on T cells with its ligands B7H1 (PDL1) and B7DC (PDL2) is known to be a mechanism of T cell inhibition. In the present study, we examined whether human or murine retinal pigment epithelial (RPE) cells express B7H1 and B7DC, and if so, whether these molecules expressed on RPE cells play an inhibitory role via interaction with T cells. The transcriptional levels and surface expression of B7H1 and B7DC on human RPE cell line (ARPE-19), RPE cells freshly isolated from healthy human subjects, and murine RPE cells were studied by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry. In addition, T cells from healthy subjects were cultured with ARPE-19 for 72h in the presence or absence of monoclonal antibody (mAb) to B7H1 or B7DC, and cytokine production (IFN-gamma, IL-8, and MCP-1) was measured. Messenger RNA and cell surface protein expression of B7H1 and B7DC were demonstrated on non-stimulated ARPE-19 and freshly isolated human RPE cells, and the expression of these molecules was predominantly upregulated by treatment with IFN-gamma. In murine RPE cells, B7H1 expression was detected only when stimulated with IFN-gamma. IFN-gamma, IL-8, and MCP-1 production by T cells co-cultured with IFN-gamma-untreated or -treated ARPE-19 was significantly enhanced in the presence of anti-B7H1 mAb. These data suggest that B7H1 expressed on RPE cells plays an immunosuppressive role in ocular inflammation, which may contribute to immune privilege in the posterior segment of the eye.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981268     DOI: 10.1016/j.exer.2007.09.007

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  18 in total

1.  Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis.

Authors:  Timothy W Phares; Stephen A Stohlman; David R Hinton; Roscoe Atkinson; Cornelia C Bergmann
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

2.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

3.  Suppression of interleukin-17-producing T-helper 17 cells by retinal pigment epithelial cells.

Authors:  Sunao Sugita; Shintaro Horie; Yukiko Yamada; Yuko Kawazoe; Hiroshi Takase; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2011-07-13       Impact factor: 2.447

4.  Ocular immune privilege.

Authors:  Ru Zhou; Rachel R Caspi
Journal:  F1000 Biol Rep       Date:  2010-01-18

5.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

6.  Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.

Authors:  Timothy W Phares; Chandran Ramakrishna; Gabriel I Parra; Alan Epstein; Lieping Chen; Roscoe Atkinson; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

7.  Photoreceptor proteins initiate microglial activation via Toll-like receptor 4 in retinal degeneration mediated by all-trans-retinal.

Authors:  Hideo Kohno; Yu Chen; Brian M Kevany; Eric Pearlman; Masaru Miyagi; Tadao Maeda; Krzysztof Palczewski; Akiko Maeda
Journal:  J Biol Chem       Date:  2013-04-09       Impact factor: 5.157

8.  Good news-bad news: the Yin and Yang of immune privilege in the eye.

Authors:  John V Forrester; Heping Xu
Journal:  Front Immunol       Date:  2012-11-27       Impact factor: 7.561

9.  Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report.

Authors:  Ine Lambert; Giuseppe Fasolino; Gil Awada; Robert Kuijpers; Marcel Ten Tusscher; Bart Neyns
Journal:  BMC Ophthalmol       Date:  2021-06-05       Impact factor: 2.209

10.  A Peptide-Based Checkpoint Immunomodulator Alleviates Immune Dysfunction in Murine Polymicrobial Sepsis.

Authors:  Timothy W Phares; Vinayaka Kotraiah; Chun-Shiang Chung; Jacqueline Unsinger; Monty Mazer; Kenneth E Remy; Cecille D Browne; Peter Buontempo; Marc Mansour; James Pannucci; Alfred Ayala; Richard S Hotchkiss; Gabriel M Gutierrez
Journal:  Shock       Date:  2021-06-01       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.